Ignite Creation Date:
2025-12-24 @ 9:44 PM
Ignite Modification Date:
2025-12-25 @ 7:24 PM
Study NCT ID:
NCT03409432
Status:
COMPLETED
Last Update Posted:
2025-07-25
First Post:
2018-01-04
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma
Sponsor:
John Reneau
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-03-16
Start Date Type:
ACTUAL
Primary Completion Date:
2025-07-16
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-07-16
Completion Date Type:
ACTUAL
First Submit Date:
2018-01-04
First Submit QC Date:
None
Study First Post Date:
2018-01-24
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-07-22
Last Update Post Date:
2025-07-25
Last Update Post Date Type:
ACTUAL